These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3530782)

  • 1. Dosage adjustment for ceftazidime in patients with impaired renal function.
    van Dalen R; Vree TB; Baars AM; Termond E
    Eur J Clin Pharmacol; 1986; 30(5):597-605. PubMed ID: 3530782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function.
    Lin MS; Wang LS; Huang JD
    J Clin Pharmacol; 1989 Apr; 29(4):331-7. PubMed ID: 2656776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 May; 49(5):445-52. PubMed ID: 10792202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
    Merdjan H; Tarral A; Das S; Li J
    J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of ceftazidime in healthy and renal failure subjects].
    Leroy A; Fillastre JP; Humbert G; Borsa F; Leguy F; Spencer GR
    Presse Med; 1988 Oct; 17(37):1917-20. PubMed ID: 2973585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

  • 13. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of decreased renal function on the pharmacokinetics of ceftazidime.
    Ackerman BH; Ross J; Tofte RW; Rotschafer JC
    Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
    Lipman J; Gomersall CD; Gin T; Joynt GM; Young RJ
    J Antimicrob Chemother; 1999 Feb; 43(2):309-11. PubMed ID: 11252342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration.
    Conil JM; Georges B; Fourcade O; Seguin T; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):133-42. PubMed ID: 17416108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis.
    Davies SP; Lacey LF; Kox WJ; Brown EA
    Nephrol Dial Transplant; 1991; 6(12):971-6. PubMed ID: 1798597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies.
    Dailly E; Brun A; Kergueris MF; Victorri-Vignoli C; Milpied N; Jolliet P
    Int J Antimicrob Agents; 2006 Jun; 27(6):553-6. PubMed ID: 16698237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.